Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
5 hedge funds and large institutions have $8.88K invested in Lixte Biotechnology Warrants in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
161% more capital invested
Capital invested by funds: $3.41K → $8.88K (+$5.47K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
3.17% more ownership
Funds ownership: 3.02% → 6.19% (+3.2%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFG
Ethos Financial Group
King Of Prussia,
Pennsylvania
|
+$2.75K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$196 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EFG
1
Ethos Financial Group
King Of Prussia,
Pennsylvania
| $3K | +$2.75K | +42,105 | New |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $2.26K | -$196 | -3,001 | -7% |
|
|
3
Citadel Advisors
Miami,
Florida
| $1.99K | +$2.1K | +32,122 | New |
|
|
CS
4
Clear Street
New York
| $1.38K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $245 | +$15 | +235 | +6% |
|
|
6
Bank of America
Charlotte,
North Carolina
| – | -$5 | -100 | Closed |
|
LIXTW Hedge Fund Activity: Q2 2024 in Review
5 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q2 2024, worth a combined $8.88K — up 161% from $3.41K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LIXTW positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Ethos Financial Group, opening a new position worth an estimated $2.75K. The largest seller was Warberg Asset Management, cutting an estimated $196.
- 5 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q2 2024, up from 4 in Q1 2024.
- Funds reported $8.88K of Lixte Biotechnology Warrants stock for Q2 2024, up 161% quarter-over-quarter.
- 2 funds opened new Lixte Biotechnology Warrants positions in Q2 2024 and 1 closed out, a net change of +1 holder.
- The largest Lixte Biotechnology Warrants buyer in Q2 2024 was Ethos Financial Group, an estimated $2.75K added.
- The largest Lixte Biotechnology Warrants seller in Q2 2024 was Warberg Asset Management, an estimated $196 sold.
Based on aggregated 13F filings for Q2 2024.